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Background
The similar routes of transmission for HIV and HBV
infections place patients with either infection at greater
risk for HIV/HBV co-infection. The aim of this study was
to analyze the epidemiological, virological, immunological
and evolutive characteristics of HIV-HBV coinfected
patients in the Regional HIV/AIDS Center Iaşi.
Methods
We performed a retrospective study including 252 patients
diagnosed with HIV associated with hepatitis B virus coin-
fection evaluated in the Infectious Diseases Hospital Iaşi
between 2000-2013.
Results
HIV-HBV coinfection prevalence was 19.9%. We noticed a
slightly higher frequency of coinfection in males (53.2%),
most patients belonging to the age group 20-29 (86.5%),
the median age of the group being 25.56 years. The predo-
minant route of transmission was parenteral (57.5%), het-
erosexual being found in a significant proportion (40.1%).
The mean CD4 cell count was 246.20 cells/cmm, over
41% of the cases had levels between 200-499 CD4 cells/
cmm. Individual values of plasma HIV viral load varied
from undetectable levels up to a maximum of 4,600,000
copies/mL, with a median value of 142,906 copies/mL.
ALT levels in HIV and HBV coinfection varied between
10-323 U/L, the average being 49.90 U/L, more than 65%
of subjects with pathological levels; 218% of the total
cholesterol values were pathological, the mean for the
group was 182.58 mg/dL. Only 16.8% in the coinfected
group had serum triglyceride levels below the reference
(160 mg/dL). All patients in the HIV-HBV coinfected
group had antiretroviral therapeutic agents with dual
action anti-HIV and anti-HBV, 87.3% receiving lamivudine
alone or in coformulation; in a small number of cases
(3.6%) we opted for tenofovir.
Conclusion
The liver injury in the context of coinfection with HBV
remains a key issue in the management of patients with
HIV infection and is a major cause of mortality and
morbidity.
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